×
About 930 results

ALLMedicine™ Hypereosinophilic Syndrome Center

Research & Reviews  310 results

An Approach to Hypereosinophilic Syndrome Presenting With Cutaneous Features.
https://doi.org/10.1097/DER.0000000000000803
Dermatitis : Contact, Atopic, Occupational, Drug; Fourzali K, Yosipovitch G et. al.

Nov 19th, 2022 - Hypereosinophilic syndrome (HES) is a heterogeneous group of disorders characterized by persistent peripheral hypereosinophilia and eosinophilia-mediated tissue damage. Hypereosinophilic syndrome can have life-threatening effects on multiple organ...

Intermittent Soft-Tissue Tumor Enlargement in Episodic Angioedema With Eosinophilia Syn...
https://doi.org/10.1097/DAD.0000000000002237
The American Journal of Dermatopathology; Fernández LT, Ocampo-Candiani J et. al.

Nov 18th, 2022 - Episodic hypereosinophilia and angioedema syndrome, also known as Gleich syndrome, is a rare entity characterized by recurrent episodes of eosinophilia, angioedema, urticaria, fever and weight gain with spontaneous resolution. It is classified as ...

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
https://clinicaltrials.gov/ct2/show/NCT00044304

Oct 14th, 2022 - This study will evaluate the safety and effectiveness of imatinib mesylate in reducing the number of eosinophils (a type of white blood cell) in patients with hypereosinophilic syndrome (HES). Patients with HES have elevated counts of eosinophils ...

Mepolizumab in Episodic Angioedema With Eosinophilia
https://clinicaltrials.gov/ct2/show/NCT04128371

Oct 14th, 2022 - Episodic angioedema with eosinophilia (EAE), also known as Gleich s Syndrome,is a rare disorder characterized by recurrent episodes of urticaria, fever, angioedema, weight gain and dramatic eosinophilia that occur at 3- to 6-week intervals and res...

Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)
https://clinicaltrials.gov/ct2/show/NCT04965636

Oct 12th, 2022 - The purpose of this study is to investigate the efficacy and safety of mepolizumab in children and adolescents with hypereosinophilic syndrome (HES) who are receiving standard of care (SoC) therapy.

see more →

Drugs  18 results see all →

Clinicaltrials.gov  27 results

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
https://clinicaltrials.gov/ct2/show/NCT00044304

Oct 14th, 2022 - This study will evaluate the safety and effectiveness of imatinib mesylate in reducing the number of eosinophils (a type of white blood cell) in patients with hypereosinophilic syndrome (HES). Patients with HES have elevated counts of eosinophils ...

Mepolizumab in Episodic Angioedema With Eosinophilia
https://clinicaltrials.gov/ct2/show/NCT04128371

Oct 14th, 2022 - Episodic angioedema with eosinophilia (EAE), also known as Gleich s Syndrome,is a rare disorder characterized by recurrent episodes of urticaria, fever, angioedema, weight gain and dramatic eosinophilia that occur at 3- to 6-week intervals and res...

Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)
https://clinicaltrials.gov/ct2/show/NCT04965636

Oct 12th, 2022 - The purpose of this study is to investigate the efficacy and safety of mepolizumab in children and adolescents with hypereosinophilic syndrome (HES) who are receiving standard of care (SoC) therapy.

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
https://clinicaltrials.gov/ct2/show/NCT03801434

Oct 7th, 2022 - PRIMARY OBJECTIVES: I. To determine the overall hematologic response rate to ruxolitinib in patients with hypereosinophilic syndrome and primary eosinophilic disorders. SECONDARY OBJECTIVES: I. To determine safety profile of ruxolitinib in patient...

A Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)
https://clinicaltrials.gov/ct2/show/NCT04191304

Sep 28th, 2022 - This is a multicentre, randomised, double-blind (DB), parallel-group, placebo-controlled, 24-week Phase 3 study to compare the efficacy and safety of benralizumab versus placebo administered by SC injection Q4W in patients with hypereosinophilic s...

see more →

News  9 results

Next Generation of PDGFR Inhibitors Makes Headway in GIST
https://www.onclive.com/view/next-generation-of-pdgfr-inhibitors-makes-headway-in-gist

May 25th, 2021 - Dysregulated platelet-derived growth factor receptor (PDGFR) signaling is implicated in a number of cancer types and is among the targets of many FDA-approved multikinase inhibitors.1,2 Despite the success of these drugs in a range of malignancies...

Dr. Mesa on Upcoming Updates to NCCN Guideline for MPNs
https://www.onclive.com/view/dr-mesa-on-upcoming-updates-to-nccn-guideline-for-mpns

Dec 20th, 2020 - Ruben A. Mesa, MD, chair of Hematology, Mayo Clinic, discusses updates that are expected in 2017 to the NCCN Guideline for Myeloproliferative Neoplasms (MPNs). The NCCN Guidelines for Myeloproliferative Neoplasms (version 1.2017), which include t...

FDA OKs Mepolizumab (Nucala) for Hypereosinophilic Syndrome
https://www.medscape.com/viewarticle/938221

Sep 28th, 2020 - The US Food and Drug Administration (FDA) has expanded the indication for mepolizumab (Nucala, GlaxoSmithKline) to include patients with hypereosinophilic syndrome (HES). Mepolizumab is indicated for adults and children aged 12 years and older wit...

FDA OKs Mepolizumab (Nucala) for Hypereosinophilic Syndrome
https://www.staging.medscape.com/viewarticle/938221

Sep 28th, 2020 - The US Food and Drug Administration (FDA) has expanded the indication for mepolizumab (Nucala, GlaxoSmithKline) to include patients with hypereosinophilic syndrome (HES). Mepolizumab is indicated for adults and children aged 12 years and older wit...

CHMP recommends approval of generic imatinib
https://www.mdedge.com/hematology-oncology/article/185423/cythemias/chmp-recommends-approval-generic-imatinib
HT Staff

Sep 18th, 2017 - Photo by Patrick Pelletier Imatinib tablet cut with a pill splitter The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for Imatinib Teva B. V.

see more →

Patient Education  8 results see all →